XML 30 R13.htm IDEA: XBRL DOCUMENT v3.23.3
SEGMENT AND GEOGRAPHIC INFORMATION
 12 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
SEGMENT AND GEOGRAPHIC INFORMATION SEGMENT AND GEOGRAPHIC INFORMATION
As a result of our strategic acquisition of Envigo in November 2021, which added a complementary research model platform, our full spectrum solutions span two segments: DSA and RMS.
Through our DSA segment, we support the discovery, non-clinical and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, but also including biotherapeutics and biomedical devices. Our scientists have the skills in analytical instrumentation development, chemistry, computer software development, histology, pathology, physiology, surgery, analytical chemistry, drug metabolism, pharmacokinetics, and toxicology to make the services and products we provide increasingly valuable to our current and potential clients. Our principal clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic research from small start-up biotechnology companies to some of the largest global pharmaceutical companies.
Through our RMS segment, we offer access to a wide range of high-quality small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. We combine deep animal husbandry expertise and expanded access to scientists across the discovery and preclinical continuum, which reduces nonclinical lead times and provides enhanced project delivery. In conjunction with our DSA segment, we have the ability to run selected nonclinical studies directly on-site at closely located research model facilities and have access to innovative genetically engineered models and services solutions. We have long-standing relationships with our principal clients, which include biopharmaceutical companies, contract research organizations ("CRO"), and academic and government organizations.
Segment Information
Revenue and other financial information by segment for the fiscal years ended September 30, 2023 and September 30, 2022 are as follows:
During the fiscal years ended September 30, 2023 and September 30, 2022, the RMS segment recognized intersegment revenue of $8,793 and $7,250, respectively, related to sales to the DSA segment. The following table presents revenue and other financial information by reportable segment for the fiscal years ended September 30, 2023 and 2022:
Fiscal Year Ended
September 30,
2023		Fiscal Year Ended
September 30,
2022
Revenue
DSA:
Service revenue$180,348 $161,113 
Product revenue4,742 4,176 
RMS:
Service revenue43,465 41,865 
Product revenue343,870 340,502 
$572,425 $547,656 
Operating Income (Loss)
DSA$15,246 $22,330 
RMS(24,904)(189,346)
Unallocated Corporate(71,802)(96,436)
$(81,460)$(263,452)
Interest expense(43,019)(29,704)
Other income (expense)237 (59,293)
Loss before income taxes$(124,242)$(352,449)
Fiscal Year Ended
September 30,
2023		Fiscal Year Ended
September 30,
2022
Depreciation and amortization:
DSA$16,371 $13,553 
RMS38,288 35,771 
Unallocated Corporate58 — 
$54,717 $49,324 
Capital expenditures:
DSA$13,314 $16,224 
RMS14,189 20,076 
$27,503 $36,300 
As a result of the application of ASC 805 for the Envigo and OBRC acquisitions, we recognized $679 and $10,246 of amortization of inventory step-up during the fiscal years ended September 30, 2023 and September 30, 2022, respectively, which were reflected in the RMS reportable segment.
During the fiscal years ended September 30, 2023 and 2022, we recognized goodwill impairment charges of $66,367 and $236,005, respectively, which were reflected in the RMS reportable segment. Refer to Note 6 - Goodwill and Intangible Assets for further discussion of the goodwill impairment charge.
During the fiscal years ended September 30, 2023 and 2022, we recognized $7,844 and $24,202, respectively, of non-cash stock-based compensation expense, which were reflected in unallocated corporate expenses, and a loss of $0 and $56,714, respectively, on fair value remeasurement of embedded derivative, which were reflected in other (expense) income. Other unallocated corporate operating expenses include compensation and other employee-related expenses, certain external professional fees, insurance, information technology-related fees and acquisition and integration costs.
The following represents total assets by segment:
Fiscal Year Ended
September 30,
2023		Fiscal Year Ended
September 30,
2022
DSA$304,015 $280,308 
RMS552,515 682,592 
$856,530 $962,900 
Geographic Information
The following represents revenue originating in entities physically located in the identified geographic area:
Fiscal Year Ended
September 30,
2023		Fiscal Year Ended
September 30,
2022
United States$482,630 $471,886 
Netherlands54,088 42,361 
Other35,707 33,409 
$572,425 $547,656 
Long-lived assets shown below include property and equipment, net. The following represents long-lived assets where they are physically located:
As of
September 30,		As of
September 30,
20232022
United States$178,021 $173,417 
Netherlands6,656 5,824 
Other6,391 6,958 
$191,068 $186,199